Use of des-aspartate-angiotensin i to treat patients exhibiting inflammatory diseases and their symptoms

Abstract

The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

1 - 56 . (canceled) 
     
     
         57 . A method for treatment and/or prevention of inflammatory diseases and pathologies or diseases that are inflammatory in nature in a subject in need of such treatment and/or prevention comprising administering to the subject an effective amount of des-aspartate-angiotensin I or its derivatives. 
     
     
         58 . The method of  claim 57  wherein the inflammatory diseases and pathologies or diseases that are inflammatory in nature are selected from the group consisting of
 1.) diseases resulting from exposure to a vesicant or toxic chemical that causes systemic and/or localized inflammation; 
 2.) skeletal muscle damage that resulted from unaccustomed or excessive strenuous use or exercise; 
 3.) heat stroke that resulted from exposure to high ambient temperature or strenuous exercise; 
 4.) Parkinson's disease or degenerative brain conditions resulting from inflammation; 
 5.) diseases that are caused by over-expressed proinflammatory cytokines; 
 6.) diseases that are caused by overproduction of ROS; 
 7.) diseases that are caused by LPS or gram negative bacteria that produce LPS; 
 8.) malignant and invasive growth, tumor, tumor metastasis or cancer; 
 9.) inflammatory diseases that are ameliorated or cured by the agonistic action of des-aspartate-angiotensin I and/or its derivatives on the angiotensin AT1 receptor in which PGE2 and PG12 are produced by COX1. 
 
     
     
         59 . The method according to  claim 58 , wherein des-aspartate-angiotensin I or its derivatives is administered in conjunction with at least one pharmaceutical agent.